Christopher B. Fox

8.3k total citations · 1 hit paper
110 papers, 5.3k citations indexed

About

Christopher B. Fox is a scholar working on Immunology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Christopher B. Fox has authored 110 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Immunology, 40 papers in Molecular Biology and 34 papers in Infectious Diseases. Recurrent topics in Christopher B. Fox's work include Immunotherapy and Immune Responses (31 papers), Immune Response and Inflammation (25 papers) and SARS-CoV-2 and COVID-19 Research (12 papers). Christopher B. Fox is often cited by papers focused on Immunotherapy and Immune Responses (31 papers), Immune Response and Inflammation (25 papers) and SARS-CoV-2 and COVID-19 Research (12 papers). Christopher B. Fox collaborates with scholars based in United States, Canada and Switzerland. Christopher B. Fox's co-authors include Steven G. Reed, Mark T. Orr, Malcolm S. Duthie, Derek T. O’Hagan, Thomas S. Vedvick, Joel M. Harris, Hillarie Plessner Windish, Rhea N. Coler, Harm HogenEsch and Darrick Carter and has published in prestigious journals such as Science, Journal of the American Chemical Society and Nature Medicine.

In The Last Decade

Christopher B. Fox

105 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Key roles of adjuvants in modern vaccines

2013 1.1k citations Steven G. Reed, Mark T. Orr et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher B. Fox United States	38	2.8k	2.0k	1.3k	1.2k	525	110	5.3k
Dennis Christensen Denmark	39	3.0k 1.1×	2.1k 1.1×	1.0k 0.8×	938 0.8×	209 0.4×	144	5.1k
Mariusz Skwarczyński Australia	42	1.9k 0.7×	2.8k 1.4×	797 0.6×	566 0.5×	877 1.7×	162	5.4k
Else Marie Agger Denmark	48	4.8k 1.7×	2.6k 1.3×	3.1k 2.4×	2.2k 1.9×	216 0.4×	101	7.4k
Kevin J. Whaley United States	37	1.0k 0.4×	1.7k 0.9×	1.2k 0.9×	1.1k 1.0×	326 0.6×	103	5.1k
Gideon Kersten Netherlands	44	1.8k 0.7×	2.6k 1.3×	1.1k 0.8×	1.2k 1.0×	269 0.5×	125	6.3k
Azam Bolhassani Iran	30	1.2k 0.4×	2.6k 1.3×	500 0.4×	756 0.7×	327 0.6×	196	4.6k
Sylvie Bertholet United States	37	2.5k 0.9×	1.5k 0.8×	1.3k 1.0×	1.8k 1.6×	1.4k 2.6×	60	5.0k
Anke Huckriede Netherlands	37	1.6k 0.6×	1.3k 0.7×	822 0.6×	1.6k 1.4×	165 0.3×	117	4.0k
Tadaki Suzuki Japan	39	1.3k 0.5×	1.3k 0.7×	3.3k 2.5×	1.5k 1.3×	535 1.0×	224	6.3k
Rhea N. Coler United States	46	3.1k 1.1×	1.6k 0.8×	2.6k 2.0×	2.9k 2.5×	1.8k 3.4×	133	6.7k

Countries citing papers authored by Christopher B. Fox

Since Specialization

Citations

This map shows the geographic impact of Christopher B. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher B. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher B. Fox more than expected).

Fields of papers citing papers by Christopher B. Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher B. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher B. Fox. The network helps show where Christopher B. Fox may publish in the future.

Co-authorship network of co-authors of Christopher B. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher B. Fox. A scholar is included among the top collaborators of Christopher B. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher B. Fox. Christopher B. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Haibo, et al.. (2026). Mucosal vaccination in mice provides protection from diverse respiratory threats. Science. eaea1260–eaea1260.

Ordoubadi, Mani, Hui Wang, Alana Gerhardt, et al.. (2025). A Thermostable nasal spray dried COVID vaccine candidate. International Journal of Pharmaceutics. 685. 126240–126240.

Moreau, G. Brett, et al.. (2025). Enhanced immunogenicity of a Clostridioides difficile TcdB vaccine adjuvanted with a synthetic dual-TLR ligand adjuvant. npj Vaccines. 10(1). 33–33. 2 indexed citations

Wang, Hui, Béla Reiz, Jing Zheng, et al.. (2025). Characterization of Spray-Dried Powders Using a Coated Alberta Idealized Nasal Inlet. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 38(1). 1–12. 3 indexed citations

Pollet, Jeroen, Jessica A. White, Brian Keegan, et al.. (2024). Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine. SHILAP Revista de lepidopterología. 4. 1342518–1342518.

Abhyankar, Mayuresh M., Deborah Chavez, Anna Goodroe, et al.. (2024). Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques. Human Vaccines & Immunotherapeutics. 20(1). 2374147–2374147. 1 indexed citations

Phoolcharoen, Waranyoo, Balamurugan Shanmugaraj, Narach Khorattanakulchai, et al.. (2023). Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant. Vaccine. 41(17). 2781–2792. 12 indexed citations

Sagawa, Zachary K., Azra Blazevic, Janice Tennant, et al.. (2023). Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults. Nature Communications. 14(1). 1138–1138. 20 indexed citations

Archer, Michelle, Hong Liang, Dawn M. Fedor, et al.. (2023). Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine. Heliyon. 9(6). e17325–e17325. 1 indexed citations

10.

Fisher, Karl J., Raodoh Mohamath, Tony Phan, et al.. (2023). Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions. npj Vaccines. 8(1). 14–14. 18 indexed citations

11.

Summers, James W., Helena Henke, Tony Phan, et al.. (2023). Screening of Oligomeric (Meth)acrylate Vaccine Adjuvants Synthesized via Catalytic Chain Transfer Polymerization. Polymers. 15(18). 3831–3831.

12.

Fox, Christopher B., et al.. (2023). Physicochemical and immunological effects of adjuvant formulations with snake venom antigens for immunization of horses for antivenom production. Toxicon. 232. 107229–107229. 2 indexed citations

13.

Gerhardt, Alana, Emily A. Voigt, Michelle Archer, et al.. (2022). A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery. Molecular Therapy — Methods & Clinical Development. 25. 205–214. 56 indexed citations

14.

Fox, Christopher B., et al.. (2020). A Two-Step Orthogonal Chromatographic Process for Purifying the Molecular Adjuvant QS-21 with High Purity and Yield. Journal of Chromatography A. 1635. 461705–461705. 11 indexed citations

15.

Fox, Christopher B., Neal Van Hoeven, Brian Granger, et al.. (2019). Vaccine adjuvant activity of emulsified oils from species of the Pinaceae family. Phytomedicine. 64. 152927–152927. 10 indexed citations

16.

Reed, Steven G., Darrick Carter, Corey Casper, Malcolm S. Duthie, & Christopher B. Fox. (2018). Correlates of GLA family adjuvants’ activities. Seminars in Immunology. 39. 22–29. 37 indexed citations

17.

Allen, James D., Simon O. Owino, Donald M. Carter, et al.. (2017). Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines. Vaccine. 35(38). 5209–5216. 20 indexed citations

18.

Noe, Amy R., Diego A. Espinosa, Xiangming Li, et al.. (2014). A Full-Length Plasmodium falciparum Recombinant Circumsporozoite Protein Expressed by Pseudomonas fluorescens Platform as a Malaria Vaccine Candidate. PLoS ONE. 9(9). e107764–e107764. 39 indexed citations

19.

Misquith, Ayesha, et al.. (2013). In vitro evaluation of TLR4 agonist activity: Formulation effects. Colloids and Surfaces B Biointerfaces. 113. 312–319. 41 indexed citations

20.

Fox, Christopher B., James Chesko, Thomas S. Vedvick, et al.. (2012). Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy. Influenza and Other Respiratory Viruses. 7(5). 815–826. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact